Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Robin E Offord

Showing results (1-10 of 14) with videos related to

Pageof 2
Sort By:
Current Protein & Peptide Science|June 25, 2005
Engineering chemokines to develop optimized HIV inhibitorsOliver Hartley, Robin E Offord
Nature Reviews. Immunology|April 28, 2006
Microbicides and other topical strategies to prevent vaginal transmission of HIVMichael M Lederman, Robin E Offord, Oliver Hartley
Plos One|July 16, 2011
Resistance to the CCR5 inhibitor 5P12-RANTES requires a difficult evolution from CCR5 to CXCR4 coreceptor useRebecca Nedellec, Mia Coetzer, Michael M Lederman, et al.
Journal of Virology|March 26, 2010
"Resistance" to PSC-RANTES revisited: two mutations in human immunodeficiency virus type 1 HIV-1 SF162 or simian-human immunodeficiency virus SHIV SF162-p3 do not confer resistanceRebecca Nedellec, Mia Coetzer, Michael M Lederman, et al.
Antimicrobial Agents and Chemotherapy|January 25, 2003
Two mechanisms for human immunodeficiency virus type 1 inhibition by N-terminal modifications of RANTESCristina Pastore, Gastón R Picchio, Francesco Galimi, et al.
Molecular Pharmaceutics|July 18, 2013
Using glycosaminoglycan/chemokine interactions for the long-term delivery of 5P12-RANTES in HIV preventionNick X Wang, Scott F Sieg, Michael M Lederman, et al.
Journal of Virology|July 13, 2012
CCR5 mutations distinguish N-terminal modifications of RANTES (CCL5) with agonist versus antagonist activityWon-Tak Choi, Rebecca Nedellec, Mia Coetzer, et al.
Journal of Controlled Release : Official Journal of the Controlled Release Society|February 8, 2019
Vaginal rings with exposed cores for sustained delivery of the HIV CCR5 inhibitor 5P12-RANTESJohn W McBride, Peter Boyd, Nicola Dias, et al.
Antimicrobial Agents and Chemotherapy|August 9, 2017
Pharmacokinetics of the Protein Microbicide 5P12-RANTES in Sheep following Single-Dose Vaginal Gel AdministrationJohn W McBride, Nicola Dias, David Cameron, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|November 8, 2008
Chemokine analogues show suitable stability for development as microbicidesFabrice Cerini, Alan Landay, Carolyne Gichinga, et al.
Pageof 2

Showing results (1-10 of 14) with videos related to

Sort By:
Pageof 2
Current Protein & Peptide Science|June 25, 2005
Engineering chemokines to develop optimized HIV inhibitorsOliver Hartley, Robin E Offord
Nature Reviews. Immunology|April 28, 2006
Microbicides and other topical strategies to prevent vaginal transmission of HIVMichael M Lederman, Robin E Offord, Oliver Hartley
Plos One|July 16, 2011
Resistance to the CCR5 inhibitor 5P12-RANTES requires a difficult evolution from CCR5 to CXCR4 coreceptor useRebecca Nedellec, Mia Coetzer, Michael M Lederman, et al.
Journal of Virology|March 26, 2010
"Resistance" to PSC-RANTES revisited: two mutations in human immunodeficiency virus type 1 HIV-1 SF162 or simian-human immunodeficiency virus SHIV SF162-p3 do not confer resistanceRebecca Nedellec, Mia Coetzer, Michael M Lederman, et al.
Antimicrobial Agents and Chemotherapy|January 25, 2003
Two mechanisms for human immunodeficiency virus type 1 inhibition by N-terminal modifications of RANTESCristina Pastore, Gastón R Picchio, Francesco Galimi, et al.
Molecular Pharmaceutics|July 18, 2013
Using glycosaminoglycan/chemokine interactions for the long-term delivery of 5P12-RANTES in HIV preventionNick X Wang, Scott F Sieg, Michael M Lederman, et al.
Journal of Virology|July 13, 2012
CCR5 mutations distinguish N-terminal modifications of RANTES (CCL5) with agonist versus antagonist activityWon-Tak Choi, Rebecca Nedellec, Mia Coetzer, et al.
Journal of Controlled Release : Official Journal of the Controlled Release Society|February 8, 2019
Vaginal rings with exposed cores for sustained delivery of the HIV CCR5 inhibitor 5P12-RANTESJohn W McBride, Peter Boyd, Nicola Dias, et al.
Antimicrobial Agents and Chemotherapy|August 9, 2017
Pharmacokinetics of the Protein Microbicide 5P12-RANTES in Sheep following Single-Dose Vaginal Gel AdministrationJohn W McBride, Nicola Dias, David Cameron, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|November 8, 2008
Chemokine analogues show suitable stability for development as microbicidesFabrice Cerini, Alan Landay, Carolyne Gichinga, et al.
Pageof 2